Drug Patents owned by Zogenix Inc
1. List of Fintepla drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US10947183 | ZOGENIX INC | Fenfluramine compositions and methods of preparing the same |
Dec, 2036
(13 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9549909 | ZOGENIX INC | Method for the treatment of dravet syndrome |
May, 2033
(10 years from now) | |
| US10478442 | ZOGENIX INC | Method for the treatment of Dravet Syndrome |
May, 2033
(10 years from now) | |
| US10478441 | ZOGENIX INC | Method for the treatment of Dravet syndrome |
May, 2033
(10 years from now) | |
| US9603815 | ZOGENIX INC | Method for the treatment of Dravet syndrome |
May, 2033
(10 years from now) | |
| US9610260 | ZOGENIX INC | Method for the treatment of Dravet Syndrome |
May, 2033
(10 years from now) | |
| US9603814 | ZOGENIX INC | Method for the treatment of Dravet syndrome |
May, 2033
(10 years from now) | |
|
US9603815
(Pediatric) | ZOGENIX INC | Method for the treatment of Dravet syndrome |
Nov, 2033
(10 years from now) | |
|
US10478441
(Pediatric) | ZOGENIX INC | Method for the treatment of Dravet syndrome |
Nov, 2033
(10 years from now) | |
|
US10478442
(Pediatric) | ZOGENIX INC | Method for the treatment of Dravet Syndrome |
Nov, 2033
(10 years from now) | |
|
US9603814
(Pediatric) | ZOGENIX INC | Method for the treatment of Dravet syndrome |
Nov, 2033
(10 years from now) | |
|
US9610260
(Pediatric) | ZOGENIX INC | Method for the treatment of Dravet Syndrome |
Nov, 2033
(10 years from now) | |
|
US9549909
(Pediatric) | ZOGENIX INC | Method for the treatment of dravet syndrome |
Nov, 2033
(10 years from now) | |
| US10950331 | ZOGENIX INC | Control system for control of distribution of medication |
Sep, 2035
(12 years from now) | |
|
US10950331
(Pediatric) | ZOGENIX INC | Control system for control of distribution of medication |
Mar, 2036
(13 years from now) | |
|
US10947183
(Pediatric) | ZOGENIX INC | Fenfluramine compositions and methods of preparing the same |
Jun, 2037
(14 years from now) | |
| US10603290 | ZOGENIX INC | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same |
Aug, 2037
(14 years from now) | |
| US11040018 | ZOGENIX INC | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same |
Aug, 2037
(14 years from now) | |
| US11406606 | ZOGENIX INC | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same |
Aug, 2037
(14 years from now) | |
|
US11040018
(Pediatric) | ZOGENIX INC | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same |
Feb, 2038
(15 years from now) | |
|
US11406606
(Pediatric) | ZOGENIX INC | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same |
Feb, 2038
(15 years from now) | |
|
US10603290
(Pediatric) | ZOGENIX INC | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same |
Feb, 2038
(15 years from now) | |
| US10452815 | ZOGENIX INC | Control system for control of distribution of medication |
Jun, 2038
(15 years from now) | |
|
US10452815
(Pediatric) | ZOGENIX INC | Control system for control of distribution of medication |
Dec, 2038
(15 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Jun 25, 2027 |
| New Product (NP) | Jun 25, 2023 |
| New Indication (I) | Mar 25, 2025 |
| Pediatric Exclusivity (PED) | Dec 25, 2027 |
Drugs and Companies using FENFLURAMINE HYDROCHLORIDE ingredient
Market Authorisation Date: 25 June, 2020
Treatment: Use in combination with stiripentol, valproate, and clobazam for the treatment of seizures associated with dravet syndrome; Use in combination with stiripentol for the treatment of seizures associated with dravet syndrome; Treatment of refractory epilepsy patients with fenfluramine that reduces the risk of cardiovascular toxicity by using cardiac monitoring and restricted distribution; Use in combination with cannabidiol for the treatment of seizures associated with dravet syndrome; Use of fenfluramine at reduced amounts with stiripentol for the treatment of seizures associated with dravet syndrome; Use of fenfluramine at reduced amounts with stiripentol for the treatment of seizures associated with lennox gastaut syndrome; Use of cardiac monitoring and restricted distribution of fenfluramine to mitigate risk of cardiovascular toxicity in the treatment of seizures associated with dravet syndrome
Dosage: SOLUTION;ORAL
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic